Bristol Myers Squibb Company $BMY Stock: Kestra Advisory Services LLC Grows Stake

Kestra Advisory Services LLC boosted its stake in shares of Bristol Myers Squibb Company (NYSE:BMY) by 13.5% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 260,476 shares of the biopharmaceutical company’s stock after purchasing an additional 30,977 shares during the quarter. Kestra Advisory Services LLC’s holdings in Bristol Myers Squibb were worth $16,254,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Primecap Management Co. CA bought a new position in shares of Bristol Myers Squibb in the second quarter valued at approximately $1,436,115,000. Legal & General Group Plc bought a new stake in shares of Bristol Myers Squibb during the 2nd quarter worth $980,862,000. BlackRock Inc. boosted its holdings in shares of Bristol Myers Squibb by 5.1% during the 2nd quarter. BlackRock Inc. now owns 180,384,994 shares of the biopharmaceutical company’s stock worth $10,393,783,000 after buying an additional 8,702,106 shares during the period. State Street Corp grew its stake in Bristol Myers Squibb by 7.3% in the 2nd quarter. State Street Corp now owns 105,757,638 shares of the biopharmaceutical company’s stock valued at $6,093,755,000 after buying an additional 7,192,724 shares during the last quarter. Finally, Caisse de depot et placement du Quebec acquired a new position in Bristol Myers Squibb in the 2nd quarter valued at $243,646,000. Institutional investors and hedge funds own 76.41% of the company’s stock.

Bristol Myers Squibb Trading Up 0.1%

Shares of BMY opened at $62.20 on Monday. The stock’s 50-day moving average price is $62.34 and its 200 day moving average price is $60.11. The company has a quick ratio of 1.44, a current ratio of 1.59 and a debt-to-equity ratio of 1.79. The firm has a market capitalization of $127.15 billion, a price-to-earnings ratio of 13.79, a P/E/G ratio of 0.32 and a beta of 0.20. Bristol Myers Squibb Company has a 12-month low of $45.26 and a 12-month high of $68.64.

Bristol Myers Squibb (NYSE:BMY) last announced its quarterly earnings data on Thursday, October 29th. The biopharmaceutical company reported $1.35 EPS for the quarter, topping analysts’ consensus estimates of $1.10 by $0.25. Bristol Myers Squibb had a return on equity of 60.48% and a net margin of 18.47%. The company had revenue of $13.07 billion during the quarter, compared to the consensus estimate of $12.72 billion. During the same quarter last year, the company earned $1.63 EPS. The company’s quarterly revenue was up 6.9% on a year-over-year basis. As a group, research analysts predict that Bristol Myers Squibb Company will post 6.45 earnings per share for the current year.

Bristol Myers Squibb Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Monday, November 2nd. Investors of record on Friday, October 2nd were paid a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a dividend yield of 4.1%. The ex-dividend date was Friday, October 2nd. Bristol Myers Squibb’s dividend payout ratio is presently 55.88%.

More Bristol Myers Squibb News

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Bristol Myers Squibb reported 56-week Phase 3 results for Camzyos (mavacamten) in children with symptomatic obstructive hypertrophic cardiomyopathy. Sustained efficacy could support the drug’s potential in a broader patient population, though the report does not say that pediatric use has been approved. Article: Bristol-Myers Squibb Says Camzyos Shows Sustained Efficacy in Phase 3 Pediatric Trial
• Positive Sentiment: A multi-year AI alliance expands the company’s neuroscience efforts, potentially supporting future drug discovery, although the supplied report gives no financial terms or near-term revenue outlook. Article: Bristol Myers Squibb Expands Neuroscience Push With Multi Year AI Alliance
• Positive Sentiment: Recent coverage also highlighted FDA accelerated approval for ZENBEXUS in multiple myeloma and positive trial updates in other diseases. These developments add to the pipeline narrative, though investors may weigh how much expected optimism is already reflected in the shares. Article: Bristol Myers Squibb Wins FDA Approval
• Neutral Sentiment: A company director disclosed selling 3,800 shares. Insider sales can attract attention, but the filing alone does not establish the director’s reason or signal a change in the company’s outlook. SEC Form 4 filing
• Negative Sentiment: A dividend-focused article flags potential pressure from an expected $1.5 billion–$2 billion decline in blood-thinner sales and the company’s debt burden. That raises questions about dividend sustainability, though the article does not establish that a cut is imminent. Article: Bristol Myers Squibb Yields Over 4%. Can Its Dividend Survive 2027?

Insider Buying and Selling at Bristol Myers Squibb

In other Bristol Myers Squibb news, SVP Phil M. Holzer sold 500 shares of the business’s stock in a transaction on Tuesday, August 25th. The shares were sold at an average price of $67.50, for a total value of $33,750.00. Following the sale, the senior vice president owned 16,862 shares of the company’s stock, valued at $1,138,185. The trade was a 2.88% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Julia A. Haller sold 3,800 shares of the business’s stock in a transaction on Thursday, November 5th. The shares were sold at an average price of $63.31, for a total transaction of $240,578.00. Following the completion of the sale, the director directly owned 30,279 shares in the company, valued at $1,916,963.49. This trade represents a 11.15% decrease in their position. The disclosure for this sale is available in the SEC filing. 0.05% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on BMY shares. BMO Capital Markets reiterated a “market perform” rating on shares of Bristol Myers Squibb in a report on Monday, July 27th. JPMorgan Chase & Co. upped their price target on shares of Bristol Myers Squibb from $67.00 to $73.00 and gave the company an “overweight” rating in a report on Friday, July 31st. Weiss Ratings raised Bristol Myers Squibb from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Tuesday, August 18th. Guggenheim reiterated a “buy” rating and issued a $75.00 price objective (up from $72.00) on shares of Bristol Myers Squibb in a research note on Friday, July 31st. Finally, Royal Bank Of Canada reissued a “sector perform” rating on shares of Bristol Myers Squibb in a research report on Monday, October 19th. Two investment analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, sixteen have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $65.46.

Bristol Myers Squibb Profile

Bristol Myers Squibb is a global biopharmaceutical company that discovers, develops, manufactures and markets medicines. Its research and commercial activities focus on serious diseases, particularly cancer, blood disorders, immune-mediated conditions and cardiovascular disease.

The company’s medicines include Opdivo and Yervoy for cancer, Eliquis for preventing and treating blood clots, and Orencia for certain autoimmune conditions. Its portfolio also includes treatments for hematologic diseases and other serious illnesses.

Bristol Myers Squibb was formed in 1989 through the merger of Bristol-Myers, founded in 1887, and the E.